It has been a busy week for big ideas on drug price legislation in the US.
First, a top staffer for Speaker of the House Nancy Pelosi offered an outline of legislation that he says will...
US Drug Pricing Debate Enters Critical Phase: Two Visions For 2021
Listen to this article
If the Senate's bipartisan price reform proposal is enacted into law this year, the drug pricing agenda for the next Administration will likely be set: implementing a host of changes to Medicare Part B, Part D and Medicaid. But if it fails, then more direct price negotiation measures will likely be the new starting point.
Learn what's happening at the US FDA. On the go.
More from Pricing Debate
- • By
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
- • By
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
- • By
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
- • By
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
More from Market Access
- analysis• By
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
- • By
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
- • By
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
